Molecular diagnostics of melanoma fine-needle aspirates: A cytology-histology correlation study

American Journal of Clinical Pathology

Volumn 138, Issue 5, 2012, Pages 670-677

  Bernacki, Kurt D ^a   Betz, Bryan L ^a   Weigelin, Helmut C ^a   Lao, Christopher D ^a   Redman, Bruce G ^a   Knoepp, Stewart M ^a   Roh, Michael H ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

BRAF; Cytology; Direct smear; Fine needle aspiration; Melanoma; Molecular; V600E; V600K

Indexed keywords

B RAF KINASE; GLUTAMIC ACID; LYSINE; VALINE;

ANALYZER; ARTICLE; ASPIRATION CYTOLOGY; CANCER CYTODIAGNOSIS; CANCER DIAGNOSIS; CANCER PATIENT; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DNA PURIFICATION; GENE MUTATION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LABORATORY DEVICE; METASTATIC MELANOMA; MINIMALLY INVASIVE PROCEDURE; MOLECULAR DIAGNOSIS; MUTATIONAL ANALYSIS; NEEDLE BIOPSY; PRIORITY JOURNAL; SKIN DEFECT; TISSUE SECTION;

BIOPSY, FINE-NEEDLE; DNA MUTATIONAL ANALYSIS; HUMANS; LYMPHATIC METASTASIS; MELANOMA; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84868136618     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPEQJW3PLOOZTC     Document Type: Article

References (26)

1. Simard EP, Ward EM, Siegel R. Cancers with increasing incidence trends in the United States: 1999 through 2008 [published online ahead of print January 4, 2012]. CA Cancer J Clin.
2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute; Available at: http://seer.cancer.gov/csr/1975-2009-pops09/. Accessed September 4, 2012.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
4. Davies MA. Special issue on melanoma. Cancer J. 2012;18:115-116.
5. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-6206.
6. Nikolaou VA, Stratigos AJ, Flaherty KT, et al. Melanoma: new insights and new therapies. J Invest Dermatol. 2012;132:854-863.
7. Davar D, Tarhini AA, Kirkwood JM. Adjuvant therapy for melanoma. Cancer J. 2012;18:192-202.
8. Yazdi AS, Palmedo G, Flaig MJ, et al. Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol. 2003;121:1160-1162. (Pubitemid 37430987)
9. Arkenau HT, Kefford R, Long GV. Targeting BRAF for patients with melanoma. Br J Cancer. 2011;104:392-398.
10. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002;62:6997-7000. (Pubitemid 35424092)
11. Flaherty KT. Narrative review: BRAF opens the door for therapeutic advances in melanoma. Ann Intern Med. 2010;153:587-591.
12. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809-819.
13. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29s:1239-1246.
14. Rubinstein JC, Sznol M, Pavlick AC, et al. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med. 2010;8:67.
15. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.
16. Cangiarella J, Symmans WF, Shapiro RL, et al. Aspiration biopsy and the clinical management of patients with malignant melanoma and palpable regional lymph nodes. Cancer. 2000;90:162-166. (Pubitemid 30438949)
17. Murali R, Doubrovsky A, Watson GF, et al. Diagnosis of metastatic melanoma by fine-needle biopsy: analysis of 2,204 cases. Am J Clin Pathol. 2007;127:385-397. (Pubitemid 46806332)
18. Murali R, Loughman NT, McKenzie PR, et al. Cytologic features of metastatic and recurrent melanoma in patients with primary cutaneous desmoplastic melanoma. Am J Clin Pathol. 2008;130:715-723.
19. Murali R, Thompson JF, Uren RF, et al. Fine-needle biopsy of metastatic melanoma: clinical use and new applications. Lancet Oncol. 2010;11:391-400.
20. Hookim K, Roh MH, Willman J, et al. Application of immunocytochemistry and BRAF mutational analysis to direct smears of metastatic melanoma. Cancer Cytopathol. 2012;120:52-61.
21. Sviatoha V, Tani E, Ghaderi M, et al. Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates from metastatic melanomas. Anticancer Res. 2010;30:3267-3272.
22. Betz BL, Roh MH, Weigelin HC, et al. The application of molecular diagnostic studies interrogating EGFR and KRAS mutations to stained cytologic smears of lung carcinoma. Am J Clin Pathol. 2011;136:564-571.
23. Billah S, Stewart J, Staerkel G, et al. EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens. Cancer Cytopathol. 2011;119:111-117.
24. Killian JK, Walker RL, Suuriniemi M, et al. Archival fine-needle aspiration cytopathology (FNAC) samples: untapped resource for clinical molecular profiling. J Mol Diagn. 2010;12:739-745.
25. Gilbert MT, Haselkorn T, Bunce M, et al. The isolation of nucleic acids from fixed, paraffin-embedded tissues: which methods are useful when. PLOS One. 2007;2:e537.
26. Halait H, DeMartin K, Shah S, et al. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma. Diagn Mol Pathol. 2012;21:1-8.